(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Select Your Cherished Fish - 2Surge of off‑lease electric vehicles expected to drive down used EV prices
- 3Australians told to continue Easter travel plans despite fuel shortages
- 4Arctic sea ice hits lowest winter level as heat records are shattered worldwide
- 5She just became the first wheelchair user to travel to space
- Tragedy in Minnesota, vaccine news, Snoop's game call: Week in review
- Bother Control Administrations for 2024: Decide for Your Home
- Spots To Go Birdwatching All over the Planet
- The Best Internet based Retailers for Style and Frill
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- Simple Consideration Plants for Home and Office: An Aide
- 6 Famous kind of practice on the planet
- Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Former Peruvian President Pedro Castillo sentenced for conspiracy
